NOTICE OF 2023 ANNUAL MEETING OF SHAREHOLDERS & PROXY STATEMENT
FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 15, 2023
This proxy statement supplement dated May 24, 2023 (the “Supplement”) supplements the Notice of 2023 Annual Meeting of Shareholders &
Proxy Statement (the “Proxy Statement”) filed by Teva Pharmaceutical Industries Limited (the “Company”) on April 19, 2023 in connection with the Company’s 2023 Annual General Meeting of Shareholders (the “Annual
Meeting”) to be held on June 15, 2023, at 4:00 p.m., Israel time / 9:00 a.m., Eastern time.
As described in Proposal 1 of the Proxy Statement,
the Board of Directors (the “Board”) recommended Dr. Sol J. Barer, Michal Braverman-Blumenstyk and Janet S. Vergis to stand for election as directors at the Annual Meeting. However, Michal Braverman-Blumenstyk, a director nominee
named in Proposal 1(b) of the Proxy Statement, informed the Company of her decision to withdraw her candidacy for personal reasons. Ms. Braverman-Blumenstyk does not currently serve on the Board. Therefore, the nomination of
Ms. Braverman-Blumenstyk is withdrawn, and no other nominee for election at the Annual Meeting will be named in place of Ms. Braverman-Blumenstyk in the Proxy.
Following the withdrawal of Ms. Braverman-Blumenstyk’s nomination, the composition of the Board, subject to the approval by shareholders of Proposal
1 to the Proxy Statement, will consist of 10 directors as follows:
| |
• |
|
9 out of 10 of our directors will be independent under NYSE regulations. |
| |
• |
|
We will continue to have three directors who identify as female out of 10 members serving on our Board, the
average tenure will be reduced to 6 years of service, and the average age of our directors will be reduced to 61.9 years. |
Voting
Matters
The form of proxy card included in the Company’s definitive proxy materials remains valid, notwithstanding the withdrawal of
Ms. Braverman-Blumenstyk as a director nominee under Proposal 1(b). Proxy cards and voting instruction forms already returned by holders of the Company’s ordinary shares or ADSs will remain valid and will be voted at the Annual Meeting
unless revoked. Proxy cards and voting instruction forms received in respect of the election of Ms. Braverman-Blumenstyk under Proposal 1(b) will not be voted with respect to her election, but will continue to be voted as directed or otherwise
as set forth therein and in the Proxy Statement with respect to all matters properly brought before the Annual Meeting, including the election of the other director nominees.
If you have already returned your proxy card or provided voting instructions, you do not need to take any action unless you wish to change your vote in
connection with any other matter brought before the Annual Meeting by submitting a new proxy card or voting instruction. If you have not yet returned your proxy card or submitted your voting instructions, please complete and return the proxy card or
submit voting instructions, disregarding Proposal 1(b) naming Ms. Braverman-Blumenstyk as a nominee for election as director.
None of the other
proposals to be presented at the Annual Meeting, as described in the Proxy Statement, are affected by this Supplement, and you should carefully review the Proxy Statement prior to voting. Information regarding the Annual Meeting and how to vote your
ordinary shares or ADSs, or revoke your proxy or voting instructions, is available in the Proxy Statement. The Proxy Statement is also available on the Company’s website at www.tevapharm.com/2023proxymaterials. This Supplement is being
made available online at the same location on or about May 24, 2023.